Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based on 18F-FDG PET and thin-section CT radiomics with machine learning

被引:0
|
作者
Li, Jianbo [1 ]
Shi, Qin [2 ]
Yang, Yi [2 ]
Xie, Jikui [2 ]
Xie, Qiang [2 ]
Ni, Ming [2 ]
Wang, Xuemei [1 ,2 ]
机构
[1] Inner Mongolia Med Univ, Affiliated Hosp, Dept Nucl Med, Hohhot, Peoples R China
[2] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Nucl Med, Div Life Sci & Med, Hefei, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词
nomogram; non-small cell lung cancer; PET/CT; machine learning; epidermal growth factor receptor; FACTOR RECEPTOR MUTATION; COMPUTED-TOMOGRAPHY CHARACTERISTICS; ADENOCARCINOMA;
D O I
10.3389/fonc.2025.1510386
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to develop and validate radiomics-based nomograms for the identification of EGFR mutations in non-small cell lung cancer (NSCLC).Methods A retrospective analysis was performed on 313 NSCLC patients, who were randomly divided into training (n = 250) and validation (n = 63) groups. Radiomic features were extracted from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and thin-section computed tomography (CT) scans. After selecting optimal radiomic features, four machine learning algorithms, including logistic regression (LR), random forest (RF), support vector machine (SVM), and extreme gradient boosting (XGBoost), were used to develop and validate radiomics models. A combined model, incorporating the Rad score from the best performing radiomics model with clinical and radiological features, was then formulated. Finally, the integrated nomogram was generated. Its predictive performance and clinical utility were evaluated using receiver operating characteristic curves, calibration curves, and decision curve analysis.Results Among the radiomics models, the RF model showed the best performance with AUCs of 0.785 (95% CI, 0.726-0.844) and 0.776 (95% CI, 0.662-0.889) in the training and validation groups, respectively. The AUCs of the clinical and radiological models in both groups were 0.711 (95% CI, 0.645-0.776) and 0.758 (95% CI, 0.627-0.890), and 0.632 (95% CI, 0.564-0.699) and 0.677 (95% CI, 0.531-0.822), respectively. The combined model achieved the highest AUCs of 0.872 (95% CI, 0.829-0.915) and 0.831 (95% CI, 0.723-0.940) in the training and validation groups, respectively. The DeLong test confirmed the superiority of the combined model over the other three models. Both the calibration curve and the DCA indicated that the radiomics nomogram was consistent and clinically useful.Conclusions Radiomics combined with machine learning and based on 18F-FDG PET/CT images can effectively determine EGFR mutation status in NSCLC patients. Radiomics-based nomograms provide a non-invasive and visually intuitive prediction tool for screening NSCLC patients with EGFR mutations in a clinical setting.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] A radiomics nomogram based on 18F-FDG PET/CT and clinical risk factors for the prediction of peritoneal metastasis in gastric cancer
    Xie, Jiageng
    Xue, Beihui
    Bian, Shuying
    Ji, Xiaowei
    Lin, Jie
    Zheng, Xiangwu
    Tang, Kun
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (11) : 977 - 987
  • [42] 18F-FDG PET/CT-based radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer
    Xue, Xiu-qing
    Yu, Wen-Ji
    Shi, Xun
    Shao, Xiao-Liang
    Wang, Yue-Tao
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer
    Toennies, Simone
    Toennies, Mario
    Kollmeier, Jens
    Bauer, Torsten T.
    Foerster, Gregor J.
    Kaiser, Dirk
    Wernecke, Klaus-Dieter
    Pfannschmidt, Joachim
    LUNG CANCER, 2016, 93 : 28 - 34
  • [44] Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
    Castello, Angelo
    Rossi, Sabrina
    Mazziotti, Emanuela
    Toschi, Luca
    Lopci, Egesta
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (06) : 821 - 826
  • [45] Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations
    Yang, Bin
    Ji, Hengshan
    Zhong, Jing
    Ma, Lu
    Zhong, Jian
    Dong, Hao
    Zhou, Changsheng
    Duan, Shaofeng
    Zhu, Chaohui
    Tian, Jiahe
    Zhang, Longjiang
    Wang, Feng
    Zhu, Hong
    Lu, Guangming
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [46] Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?
    Aukema, Tjeerd S.
    Kappers, Ingrid
    Olmos, Renato A. Valdes
    Codrington, Henk E.
    van Tinteren, Harm
    van Pel, Renee
    Klomp, Houke M.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1344 - 1348
  • [47] Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung
    Caiyue Ren
    Jianping Zhang
    Ming Qi
    Jiangang Zhang
    Yingjian Zhang
    Shaoli Song
    Yun Sun
    Jingyi Cheng
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1538 - 1549
  • [48] Predictive [18F]-FDG PET/CT-Based Radiogenomics Modelling of Driver Gene Mutations in Non-small Cell Lung Cancer
    Hinzpeter, Ricarda
    Kulanthaivelu, Roshini
    Kohan, Andres
    Murad, Vanessa
    Mirshahvalad, Seyed Ali
    Avery, Lisa
    Ortega, Claudia
    Metser, Ur
    Hope, Andrew
    Yeung, Jonathan
    Mcinnis, Micheal
    Veit-Haibach, Patrick
    ACADEMIC RADIOLOGY, 2024, 31 (12) : 5314 - 5323
  • [49] New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review
    Ge, Xinyu
    Gao, Jianxiong
    Niu, Rong
    Shi, Yunmei
    Shao, Xiaoliang
    Wang, Yuetao
    Shao, Xiaonan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER
    Aguloglu, Nursin
    Aksu, Aysegul
    Akyol, Murat
    Katgi, Nuran
    Doksoz, Tugce Ciftci
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2022, 61 (06): : 433 - 439